Sanamedi

About Sanamedi

Sanamedi Inc., formerly known as the Japanese Organization for Medical Device Development, Inc. (JOMDD), is a Japanese firm that operates as an incubator for medical products, commercializing medical innovation through in-house development, investment, and consulting services. The company was founded on September 12, 2012, by Dr. Takahiro Uchida, who also serves as the CEO. Dr. Uchida, a board-certified physician in internal medicine and cardiology, was the first Japanese Medical Officer at the US FDA's Center for Devices and Radiological Health. His experience includes roles at Boston Scientific Corporation, a fellowship at Harvard Clinical Research Institute, and establishing a Silicon Valley-based consulting firm for medical device startups.

Sanamedi's business model is structured around three core pillars. The first is its in-house business, where it conducts research, development, manufacturing, and sales of its own medical devices. Notable products include the "AVNeo™ Sizer System set" for aortic valve reconstruction, sold in Japan, the US, and Europe, and the "3D back scanner™" for scoliosis screening. The second pillar is investment in early-stage medical startups where Sanamedi can provide synergistic value through its commercialization expertise. The third pillar is a fee-for-service consulting business. This service offers support in areas such as business feasibility assessment, new business planning, intellectual property strategy, and regulatory affairs, with a particular strength in assisting with FDA approvals like the 510(k) application, leveraging its US subsidiary and consultants.

The company changed its name to Sanamedi, Inc. in April 2023, with "Sana" meaning health in Latin, to reflect its focus on contributing to healthy lives by anticipating changing social needs. Sanamedi covers a wide range of medical fields, including medical devices, digital health, drug discovery, and regenerative medicine. It has established partnerships with organizations like the Israeli Medical Association's Future of Medicine and Innovation (FOMI) to integrate know-how from global startup ecosystems. As of 2024, the company reports having commercialized products in over 30 countries and has supported 12 portfolio companies that have collectively raised over 16.1 billion yen.